TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Framing Messages for Smoking Cessation With Buproprion
Brief Summary: This is a randomized study of message framing in individuals beginning a smoking cessation program utilizing bupropion SR and brief counseling, videos, and pamphlets.


Options:
A: Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A
B: Arm Label: Gain Framed Absitnence Program; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion, Behavioral: Smoking Abstinence Program | Arm Label: Loss Framed Abstinence Program; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion, Behavioral: Smoking Abstinence Program | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Gain Framed Absitnence Program, Loss Framed Abstinence Program | Intervention Type: BEHAVIORAL; Name: Smoking Abstinence Program; Assigned to Arm(s): Gain Framed Absitnence Program, Loss Framed Abstinence Program
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Varenicline + Active Patch; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch, Drug: Varenicline | Arm Label: Varenicline + Placebo Patch; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Varenicline | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Varenicline + Active Patch | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Varenicline + Placebo Patch | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Patch, Varenicline + Placebo Patch

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Framing Messages for Smoking Cessation With Buproprion
Brief Summary: This is a randomized study of message framing in individuals beginning a smoking cessation program utilizing bupropion SR and brief counseling, videos, and pamphlets.


Options:
A: Arm Label: Sugar Pill; Type: PLACEBO_COMPARATOR; Interventions: Other: Sugar Pill | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Bupropion HCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion HCl | Intervention Type: OTHER; Name: Sugar Pill; Assigned to Arm(s): Sugar Pill | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Bupropion HCl; Assigned to Arm(s): Bupropion HCl
B: Intervention Type: DRUG; Name: bupropion (Wellbutrin); Assigned to Arm(s): N/A
C: Arm Label: Gain Framed Absitnence Program; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion, Behavioral: Smoking Abstinence Program | Arm Label: Loss Framed Abstinence Program; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion, Behavioral: Smoking Abstinence Program | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Gain Framed Absitnence Program, Loss Framed Abstinence Program | Intervention Type: BEHAVIORAL; Name: Smoking Abstinence Program; Assigned to Arm(s): Gain Framed Absitnence Program, Loss Framed Abstinence Program
D: Arm Label: 1 Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: 2 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1 Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Framing Messages for Smoking Cessation With Buproprion
Brief Summary: This is a randomized study of message framing in individuals beginning a smoking cessation program utilizing bupropion SR and brief counseling, videos, and pamphlets.


Options:
A: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: support and visits, Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: support and visits, Drug: placebo | Intervention Type: BEHAVIORAL; Name: support and visits; Assigned to Arm(s): placebo, varenicline | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: Treatment as Usual Group 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment as Usual Group 2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Group 1; Type: EXPERIMENTAL; Interventions: Behavioral: Computer Screening, Brief Intervention, Referral toTreatment | Arm Label: Intervention Group 2; Type: EXPERIMENTAL; Interventions: Behavioral: Computer Screening, Brief Intervention, Referral toTreatment | Intervention Type: BEHAVIORAL; Name: Computer Screening, Brief Intervention, Referral toTreatment; Assigned to Arm(s): Intervention Group 1, Intervention Group 2
C: Arm Label: DFND Program; Type: EXPERIMENTAL; Interventions: Behavioral: DFND Program | Arm Label: Informational Booklet; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: DFND Program; Assigned to Arm(s): DFND Program
D: Arm Label: Gain Framed Absitnence Program; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion, Behavioral: Smoking Abstinence Program | Arm Label: Loss Framed Abstinence Program; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion, Behavioral: Smoking Abstinence Program | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Gain Framed Absitnence Program, Loss Framed Abstinence Program | Intervention Type: BEHAVIORAL; Name: Smoking Abstinence Program; Assigned to Arm(s): Gain Framed Absitnence Program, Loss Framed Abstinence Program

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study: Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide With Standard Care to Treat Macular Edema
Brief Summary: The SCORE Study will compare the effectiveness and safety of standard care to intravitreal injection(s) of triamcinolone for treating macular edema (swelling of the central part of the retina) associated with central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO).


Options:
A: Arm Label: AVASTIN; Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab | Arm Label: OZURDEX; Type: ACTIVE_COMPARATOR; Interventions: Drug: dexamethasone | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): AVASTIN | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): OZURDEX
B: Arm Label: Dexamethasone 700 μg; Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone | Arm Label: Dexamethasone 350 μg; Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Other: Sham | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone 350 μg, Dexamethasone 700 μg | Intervention Type: OTHER; Name: Sham; Assigned to Arm(s): Sham
C: Arm Label: Dexamethasone 700 μg; Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone | Arm Label: Dexamethasone 350 μg; Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Other: Sham | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone 350 μg, Dexamethasone 700 μg | Intervention Type: OTHER; Name: Sham; Assigned to Arm(s): Sham
D: Arm Label: CRVO Observation; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Care | Arm Label: CRVO 1 mg dose triamcinolone acetonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravitreal triamcinolone injection | Arm Label: CRVO 4 mg dose triamcinolone acetonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravitreal triamcinolone injection | Arm Label: BRVO standard care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Care | Arm Label: BRVO 1 mg dose triamcinolone acetonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravitreal triamcinolone injection | Arm Label: BRVO 4 mg dose triamcinolone acetonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravitreal triamcinolone injection | Intervention Type: OTHER; Name: Standard Care; Assigned to Arm(s): BRVO standard care, CRVO Observation | Intervention Type: DRUG; Name: intravitreal triamcinolone injection; Assigned to Arm(s): BRVO 1 mg dose triamcinolone acetonide, CRVO 1 mg dose triamcinolone acetonide | Intervention Type: DRUG; Name: intravitreal triamcinolone injection; Assigned to Arm(s): BRVO 4 mg dose triamcinolone acetonide, CRVO 4 mg dose triamcinolone acetonide

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study: Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide With Standard Care to Treat Macular Edema
Brief Summary: The SCORE Study will compare the effectiveness and safety of standard care to intravitreal injection(s) of triamcinolone for treating macular edema (swelling of the central part of the retina) associated with central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO).


Options:
A: Arm Label: Bevacizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravitreal injection of bevacizumab | Arm Label: Ranibizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravitreal injection of ranibizumab (0.5 mg per dose) | Intervention Type: DRUG; Name: Intravitreal injection of bevacizumab; Assigned to Arm(s): Bevacizumab | Intervention Type: DRUG; Name: Intravitreal injection of ranibizumab (0.5 mg per dose); Assigned to Arm(s): Ranibizumab
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Avastin (Bevacizumab) | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Drug: Avastin (Bevacizumab) | Intervention Type: DRUG; Name: Avastin (Bevacizumab); Assigned to Arm(s): 1, 2
C: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
D: Arm Label: CRVO Observation; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Care | Arm Label: CRVO 1 mg dose triamcinolone acetonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravitreal triamcinolone injection | Arm Label: CRVO 4 mg dose triamcinolone acetonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravitreal triamcinolone injection | Arm Label: BRVO standard care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Care | Arm Label: BRVO 1 mg dose triamcinolone acetonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravitreal triamcinolone injection | Arm Label: BRVO 4 mg dose triamcinolone acetonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravitreal triamcinolone injection | Intervention Type: OTHER; Name: Standard Care; Assigned to Arm(s): BRVO standard care, CRVO Observation | Intervention Type: DRUG; Name: intravitreal triamcinolone injection; Assigned to Arm(s): BRVO 1 mg dose triamcinolone acetonide, CRVO 1 mg dose triamcinolone acetonide | Intervention Type: DRUG; Name: intravitreal triamcinolone injection; Assigned to Arm(s): BRVO 4 mg dose triamcinolone acetonide, CRVO 4 mg dose triamcinolone acetonide

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study: Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide With Standard Care to Treat Macular Edema
Brief Summary: The SCORE Study will compare the effectiveness and safety of standard care to intravitreal injection(s) of triamcinolone for treating macular edema (swelling of the central part of the retina) associated with central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO).


Options:
A: Arm Label: 1; Type: N/A; Interventions: Other: Examination with an OCT device | Arm Label: 2; Type: N/A; Interventions: N/A | Arm Label: 3; Type: N/A; Interventions: Other: Examination with an OCT device | Arm Label: 4; Type: N/A; Interventions: Other: Examination with an OCT device | Arm Label: 5; Type: N/A; Interventions: Other: Examination with an OCT device | Arm Label: 6; Type: N/A; Interventions: Other: Examination with an OCT device | Arm Label: 7; Type: N/A; Interventions: Other: Examination with an OCT device | Intervention Type: OTHER; Name: Examination with an OCT device; Assigned to Arm(s): 1, 3, 4, 5, 6, 7
B: Intervention Type: DRUG; Name: pegaptanib sodium; Assigned to Arm(s): N/A
C: Arm Label: Sham injection; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Arm Label: Ranibizumab injection 0.3 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab injection 0.3 mg | Arm Label: Ranibizumab injection 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab injection 0.5 mg | Intervention Type: DRUG; Name: Ranibizumab injection 0.3 mg; Assigned to Arm(s): Ranibizumab injection 0.3 mg | Intervention Type: DRUG; Name: Ranibizumab injection 0.5 mg; Assigned to Arm(s): Ranibizumab injection 0.5 mg | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): Sham injection
D: Arm Label: CRVO Observation; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Care | Arm Label: CRVO 1 mg dose triamcinolone acetonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravitreal triamcinolone injection | Arm Label: CRVO 4 mg dose triamcinolone acetonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravitreal triamcinolone injection | Arm Label: BRVO standard care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Care | Arm Label: BRVO 1 mg dose triamcinolone acetonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravitreal triamcinolone injection | Arm Label: BRVO 4 mg dose triamcinolone acetonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravitreal triamcinolone injection | Intervention Type: OTHER; Name: Standard Care; Assigned to Arm(s): BRVO standard care, CRVO Observation | Intervention Type: DRUG; Name: intravitreal triamcinolone injection; Assigned to Arm(s): BRVO 1 mg dose triamcinolone acetonide, CRVO 1 mg dose triamcinolone acetonide | Intervention Type: DRUG; Name: intravitreal triamcinolone injection; Assigned to Arm(s): BRVO 4 mg dose triamcinolone acetonide, CRVO 4 mg dose triamcinolone acetonide

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study of Aripiprazole in Patients With Major Depressive Disorder
Brief Summary: The purpose of this 14 week, randomized, double-blind, placebo controlled study is to assess the safety and efficacy of aripiprazole to placebo as adjunctive treatment to an assigned open-label marketed antidepressant therapy (ADT) in patients with Major Depressive Disorder who demonstrate an incomplete response to a prospective eight week trial of the same assigned open-label marketed antidepressant therapy.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: lamotrigine, Drug: paroxetine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Drug: paroxetine | Intervention Type: DRUG; Name: lamotrigine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: paroxetine; Assigned to Arm(s): 1, 2
B: Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: BuproprionSR; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: buspirone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Lithium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: mirtazapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: nortriptyline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: sertraline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tranylcypromine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: VenlafaxineXR; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: T3 (Triiodothyronine); Assigned to Arm(s): N/A
C: Arm Label: A1; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole+ ADT | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo+ ADT | Intervention Type: DRUG; Name: Aripiprazole+ ADT; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo+ ADT; Assigned to Arm(s): A2
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lamotrigine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Amide | Intervention Type: DRUG; Name: Lamotrigine; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Amide; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Moderate to Severe Crohn's Disease Who Have Lost Response or Are Intolerant to Infliximab
Brief Summary: The goal of this study is to test whether adalimumab can induce clinical remission in subjects with active Crohn's disease who have been initially treated with infliximab and either lost response or discontinued its use as a result of intolerance to the drug.


Options:
A: Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Certolizumab Pegol (CDP870); Assigned to Arm(s): N/A
C: Arm Label: Open-label Abatacept (ABA)-Previous User; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD) | Arm Label: Open-label ABA-Current User; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD), Drug: Anti-Tumor Necrosing Factor (TNF) Therapy | Arm Label: Long-term ABA; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD) | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Long-term ABA, Open-label ABA-Current User, Open-label Abatacept (ABA)-Previous User | Intervention Type: DRUG; Name: Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD); Assigned to Arm(s): Long-term ABA, Open-label ABA-Current User, Open-label Abatacept (ABA)-Previous User | Intervention Type: DRUG; Name: Anti-Tumor Necrosing Factor (TNF) Therapy; Assigned to Arm(s): Open-label ABA-Current User
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate, Drug: tocilizumab [RoActemra/Actemra] | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate, Drug: tocilizumab [RoActemra/Actemra] | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Placebo | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Moderate to Severe Crohn's Disease Who Have Lost Response or Are Intolerant to Infliximab
Brief Summary: The goal of this study is to test whether adalimumab can induce clinical remission in subjects with active Crohn's disease who have been initially treated with infliximab and either lost response or discontinued its use as a result of intolerance to the drug.


Options:
A: Arm Label: Any adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Any adalimumab
B: Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): N/A
C: Arm Label: DB Adalimumab 40 mg eow; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Placebo eow; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: OL Adalimumab 40 mg eow; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): DB Adalimumab 40 mg eow, OL Adalimumab 40 mg eow | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo eow
D: Arm Label: Open-label adalimumab (Week 0 to Week 4); Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Arm Label: Low-Dose Adalimumab: 20 mg or 10 mg eow (Week 4 to Week 52); Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Arm Label: High-Dose Adalimumab: 40 mg or 20 mg eow (Week 4 to Week 52); Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Open-label adalimumab (Week 0 to Week 4) | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Low-Dose Adalimumab: 20 mg or 10 mg eow (Week 4 to Week 52) | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): High-Dose Adalimumab: 40 mg or 20 mg eow (Week 4 to Week 52)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of EASYcare-based Geriatric Intermediate Care
Brief Summary: The purpose of this study is to study the effects of nursing home visits in independently living elderly people on their functional performance and health-related quality of life. The general practitioner (GP) can refer elderly people to this intervention model after identification of a problem in cognition, mood, behavior, mobility, or nutrition. A specialist geriatric nurse visits the patients at home up to six times and coaches the patient in cooperation with the GP and geriatrician.


Options:
A: Intervention Type: BEHAVIORAL; Name: Dutch EASYcare Study Geriatric Intermediate Care Programme; Assigned to Arm(s): N/A
B: Arm Label: Conventional care, controlgroup; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: integrated health care chain; Type: EXPERIMENTAL; Interventions: Other: integrated health care chain | Intervention Type: OTHER; Name: integrated health care chain; Assigned to Arm(s): integrated health care chain
C: Intervention Type: BEHAVIORAL; Name: Preventive Primary Care Outreach; Assigned to Arm(s): N/A
D: Arm Label: regular medical care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: The CareWell programme; Type: EXPERIMENTAL; Interventions: Other: The CareWell programme | Intervention Type: OTHER; Name: The CareWell programme; Assigned to Arm(s): The CareWell programme

Answer: A